Research ExplorerPublicationsMidregional Pro-A-type natriuretic peptide for diagnosis and...

Midregional Pro-A-type natriuretic peptide for diagnosis and prognosis in patients with suspected acute myocardial infarction

Standard

Midregional Pro-A-type natriuretic peptide for diagnosis and prognosis in patients with suspected acute myocardial infarction. / Meune, Christophe; Twerenbold, Raphael; Drexler, Beatrice; Balmelli, Cathrin; Wolf, Claudia; Haaf, Philip; Reichlin, Tobias; Irfan, Affan; Reiter, Miriam; Zellweger, Christa; Meissner, Julia; Stelzig, Claudia; Freese, Michael; Capodarve, Isabel; Mueller, Christian.

In: American Journal of Cardiology, Vol. 109, No. 8, 15.04.2012, p. 1117-1123.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Meune, C, Twerenbold, R, Drexler, B, Balmelli, C, Wolf, C, Haaf, P, Reichlin, T, Irfan, A, Reiter, M, Zellweger, C, Meissner, J, Stelzig, C, Freese, M, Capodarve, I & Mueller, C 2012, 'Midregional Pro-A-type natriuretic peptide for diagnosis and prognosis in patients with suspected acute myocardial infarction', American Journal of Cardiology, vol. 109, no. 8, pp. 1117-1123. https://doi.org/10.1016/j.amjcard.2011.11.047

APA

Meune, C., Twerenbold, R., Drexler, B., Balmelli, C., Wolf, C., Haaf, P., Reichlin, T., Irfan, A., Reiter, M., Zellweger, C., Meissner, J., Stelzig, C., Freese, M., Capodarve, I., & Mueller, C. (2012). Midregional Pro-A-type natriuretic peptide for diagnosis and prognosis in patients with suspected acute myocardial infarction. American Journal of Cardiology, 109(8), 1117-1123. https://doi.org/10.1016/j.amjcard.2011.11.047

Vancouver

Meune C, Twerenbold R, Drexler B, Balmelli C, Wolf C, Haaf P et al. Midregional Pro-A-type natriuretic peptide for diagnosis and prognosis in patients with suspected acute myocardial infarction. American Journal of Cardiology. 2012 Apr 15;109(8):1117-1123. https://doi.org/10.1016/j.amjcard.2011.11.047

Bibtex

@article{a241385bb7db4b63b0b1ffe6a65a90c0,
title = "Midregional Pro-A-type natriuretic peptide for diagnosis and prognosis in patients with suspected acute myocardial infarction",
abstract = "We hypothesized that midregional proA-type natriuretic peptide (MR-proANP), the stable midregional epitope of proANP, might be useful in the early diagnosis and risk stratification of patients with suspected acute myocardial infarction (AMI). In this multicenter study we measured MR-proANP, cardiac troponin T (cTnT), and high-sensitive cTnT (hs-cTnT) at presentation in 675 consecutive patients presenting to the emergency department with suspected AMI. The final diagnosis was adjudicated by 2 independent cardiologists. Patients were followed 360 days for mortality and AMI. AMI was the final diagnosis in 119 patients (18%). Median MR-proANP levels at presentation were significantly higher in patients with AMI (189 pmol/L, interquartile range 97 to 341) versus patients with another final diagnosis (83 pmol/L, 49 to 144, p <0.001). However, neither the combination of MR-proANP with cTnT nor its combination with hs-cTnT significantly improved diagnostic accuracy as quantified by area under the receiver operating characteristic curve (0.91 vs 0.89 for cTnT alone, p = 0.086; 0.95 vs 0.96 for hs-cTnT, respectively, p = 0.02). Cumulative 360-day mortality/AMI rates were 2.4% in the first, 3.6% in the second, 9.5% in the third, and 18.8% in the fourth quartiles of MR-proANP (p <0.001). MR-proANP (area under the curve 0.76) predicted mortality/AMI independently of and more accurately than cTnT (area under the curve 0.62), hs-cTnT (area under the curve 0.71), and Thrombolysis In Myocardial Infarction risk score (area under the curve 0.72). Net reclassification improvements offered by the additional use of MR-proANP were 0.388 (p <0.001), 0.425 (p <0.001), and 0.217 (p = 0.007), respectively. In conclusion, MR-proANP improves risk prediction for 360-day mortality/AMI but does not seem to help in the early diagnosis of AMI.",
author = "Christophe Meune and Raphael Twerenbold and Beatrice Drexler and Cathrin Balmelli and Claudia Wolf and Philip Haaf and Tobias Reichlin and Affan Irfan and Miriam Reiter and Christa Zellweger and Julia Meissner and Claudia Stelzig and Michael Freese and Isabel Capodarve and Christian Mueller",
year = "2012",
month = apr,
day = "15",
doi = "10.1016/j.amjcard.2011.11.047",
language = "English",
volume = "109",
pages = "1117--1123",
journal = "AM J CARDIOL",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "8",

}

RIS

TY - JOUR

T1 - Midregional Pro-A-type natriuretic peptide for diagnosis and prognosis in patients with suspected acute myocardial infarction

AU - Meune, Christophe

AU - Twerenbold, Raphael

AU - Drexler, Beatrice

AU - Balmelli, Cathrin

AU - Wolf, Claudia

AU - Haaf, Philip

AU - Reichlin, Tobias

AU - Irfan, Affan

AU - Reiter, Miriam

AU - Zellweger, Christa

AU - Meissner, Julia

AU - Stelzig, Claudia

AU - Freese, Michael

AU - Capodarve, Isabel

AU - Mueller, Christian

PY - 2012/4/15

Y1 - 2012/4/15

N2 - We hypothesized that midregional proA-type natriuretic peptide (MR-proANP), the stable midregional epitope of proANP, might be useful in the early diagnosis and risk stratification of patients with suspected acute myocardial infarction (AMI). In this multicenter study we measured MR-proANP, cardiac troponin T (cTnT), and high-sensitive cTnT (hs-cTnT) at presentation in 675 consecutive patients presenting to the emergency department with suspected AMI. The final diagnosis was adjudicated by 2 independent cardiologists. Patients were followed 360 days for mortality and AMI. AMI was the final diagnosis in 119 patients (18%). Median MR-proANP levels at presentation were significantly higher in patients with AMI (189 pmol/L, interquartile range 97 to 341) versus patients with another final diagnosis (83 pmol/L, 49 to 144, p <0.001). However, neither the combination of MR-proANP with cTnT nor its combination with hs-cTnT significantly improved diagnostic accuracy as quantified by area under the receiver operating characteristic curve (0.91 vs 0.89 for cTnT alone, p = 0.086; 0.95 vs 0.96 for hs-cTnT, respectively, p = 0.02). Cumulative 360-day mortality/AMI rates were 2.4% in the first, 3.6% in the second, 9.5% in the third, and 18.8% in the fourth quartiles of MR-proANP (p <0.001). MR-proANP (area under the curve 0.76) predicted mortality/AMI independently of and more accurately than cTnT (area under the curve 0.62), hs-cTnT (area under the curve 0.71), and Thrombolysis In Myocardial Infarction risk score (area under the curve 0.72). Net reclassification improvements offered by the additional use of MR-proANP were 0.388 (p <0.001), 0.425 (p <0.001), and 0.217 (p = 0.007), respectively. In conclusion, MR-proANP improves risk prediction for 360-day mortality/AMI but does not seem to help in the early diagnosis of AMI.

AB - We hypothesized that midregional proA-type natriuretic peptide (MR-proANP), the stable midregional epitope of proANP, might be useful in the early diagnosis and risk stratification of patients with suspected acute myocardial infarction (AMI). In this multicenter study we measured MR-proANP, cardiac troponin T (cTnT), and high-sensitive cTnT (hs-cTnT) at presentation in 675 consecutive patients presenting to the emergency department with suspected AMI. The final diagnosis was adjudicated by 2 independent cardiologists. Patients were followed 360 days for mortality and AMI. AMI was the final diagnosis in 119 patients (18%). Median MR-proANP levels at presentation were significantly higher in patients with AMI (189 pmol/L, interquartile range 97 to 341) versus patients with another final diagnosis (83 pmol/L, 49 to 144, p <0.001). However, neither the combination of MR-proANP with cTnT nor its combination with hs-cTnT significantly improved diagnostic accuracy as quantified by area under the receiver operating characteristic curve (0.91 vs 0.89 for cTnT alone, p = 0.086; 0.95 vs 0.96 for hs-cTnT, respectively, p = 0.02). Cumulative 360-day mortality/AMI rates were 2.4% in the first, 3.6% in the second, 9.5% in the third, and 18.8% in the fourth quartiles of MR-proANP (p <0.001). MR-proANP (area under the curve 0.76) predicted mortality/AMI independently of and more accurately than cTnT (area under the curve 0.62), hs-cTnT (area under the curve 0.71), and Thrombolysis In Myocardial Infarction risk score (area under the curve 0.72). Net reclassification improvements offered by the additional use of MR-proANP were 0.388 (p <0.001), 0.425 (p <0.001), and 0.217 (p = 0.007), respectively. In conclusion, MR-proANP improves risk prediction for 360-day mortality/AMI but does not seem to help in the early diagnosis of AMI.

UR - http://www.scopus.com/inward/record.url?scp=84859267264&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2011.11.047

DO - 10.1016/j.amjcard.2011.11.047

M3 - SCORING: Journal article

C2 - 22257708

AN - SCOPUS:84859267264

VL - 109

SP - 1117

EP - 1123

JO - AM J CARDIOL

JF - AM J CARDIOL

SN - 0002-9149

IS - 8

ER -